Author

D. K. Edwards

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 8 Microbiology· 8

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 16 Research Focus:host-pathogen & immune response· 16 Organism:mouse· 12 Research Focus:drug response / drug discovery· 7 Organism:human· 3 Organism:non-human primate· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2

Frequent Co-Authors

A. Carfi· 10 shared M. S. Diamond· 9 shared K. Wu· 8 shared B. Ying· 7 shared A. Choi· 6 shared C.-Y. Liang· 6 shared L. B. Thackray· 6 shared S. Elbashir· 6 shared

Activity by Year

2021-2024 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

10 shared papersImmunology

A. Carfi

Mutual co-authors in cluster

Author profile →

16 papers

Recent·Most cited

Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain

B. Ying, C.-Y. Liang, P. Desai, S. Scheaffer, S. Elbashir, D. K. Edwards, L. B. Thackray, M. S. Diamond

This study shows that boosting mice with mRNA vaccines in the ipsilateral or contralateral arm leads to equivalent immune responses and protection against SARS-CoV-2 Omicron.

Journal of Virology · Sep 17, 2024Peer-reviewedMicrobiology

Intestinal helminth infection impairs vaccine-induced T cell responses and protection against SARS-CoV-2

P. Desai, C. E. Karl, B. Ying, C.-Y. Liang, T. Garcia-Salum, A. C. Santana, F. T. Caten, J. F. Urban, S. M. Elbashir, D. K. Edwards, S. P. Ribeiro, L. B. Thackray, R.-P. K. Sekaly, M. S. Diamond

This study shows that intestinal helminth infection reduces T cell responses to an mRNA SARS-CoV-2 vaccine and weakens protection against Omicron but not the ancestral strain.

bioRxiv · Jan 14, 2024 · PreprintImmunology

Prototype mRNA vaccines imprint broadly neutralizing human serum antibodies after Omicron variant-matched boosting

C.-Y. Liang, S. Raju, Z. Liu, Y. Li, G. A. Arunkumar, J. B. Case, S. J. Zost, C. M. Acreman, D. C. Carvalho dos Anjos, J. S. McLellan, J. E. Crowe, S. P. J. Whelan, S. M. Elbashir, D. K. Edwards, M. S. Diamond

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.

bioRxiv · Jan 3, 2024 · PreprintImmunology

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection

G. Baldeon Vaca, M. Meyer, A. Cadete, C. J. Hsiao, A. Golding, A. Jeon, E. Jacquinet, E. Azcue, C. M. Guan, X. Sanchez-Felix, C. A. Pietzsch, C. E. Mire, M. A. Hyde, M. E. Comeaux, J. M. Williams, , K. Bahl

This study shows intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 by inducing antibodies and reducing viral load and lung damage.

bioRxiv · Jan 11, 2023 · PreprintImmunology

Fc-gamma receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2

S. R. Mackin, P. Desai, B. M. Whitener, C. E. Karl, M. Liu, R. S. Baric, D. K. Edwards, T. M. Chicz, R. P. McNamara, G. Alter, M. S. Diamond

This study shows that Fc-gamma receptor-dependent antibody effector functions are necessary for vaccine protection against antigenic variants of SARS-CoV-2, including Omicron.

bioRxiv · Nov 27, 2022 · PreprintMicrobiology

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains

G. Stewart-Jones, S. M. Elbashir, K. Wu, D. Lee, I. Renzi, B. Ying, M. Koch, C. E. Sein, A. Choi, B. Whitener, D. Garcia-Dominguez, C. Henry, A. Woods, L. Ma, D. Montes Berrueta, , A. Carfi

The paper develops and evaluates an mRNA vaccine, mRNA-1283, encoding SARS-CoV-2 spike N-terminal and receptor-binding domains, showing improved immunogenicity and protection against multiple variants in mice.

bioRxiv · Oct 7, 2022 · PreprintImmunology

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant

S. M. Scheaffer, D. Lee, B. Whitener, B. Ying, K. Wu, H. Jani, P. Martin, N. J. Amato, L. E. Avena, D. M. Berrueta, S. D. Schmidt, S. O'Dell, A. Nasir, G.-Y. Chuang, G. Stewart-Jones, , M. S. Diamond

This study evaluates bivalent SARS-CoV-2 mRNA vaccines and finds they induce broader neutralizing antibodies and better protection against BA.5 Omicron compared to monovalent vaccines.

bioRxiv · Sep 12, 2022 · PreprintMicrobiology

Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice

B. Ying, S. M. Scheaffer, B. Whitener, C.-Y. Liang, O. Dmytrenko, S. Mackin, K. Wu, D. Lee, L. E. Avena, Z. Chong, J. B. Case, L. Ma, T. Kim, C. Sein, A. Woods, , M. S. Diamond

This study shows that boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibodies and protection against B.1.1.529 in mice, with the Omicron-matched booster showing slightly better outcomes.

bioRxiv · Feb 7, 2022 · PreprintMicrobiology

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

A. C. Walls, L. A. VanBlargan, K. Wu, A. Choi, M. J. Navarro, D. Lee, L. Avena, D. M. Berrueta, M. N. Pham, S. Elbashir, M. C. Miranda, E. Kepl, M. Johnson, A. Blackstone, K. R. Sprouse, , D. Veesler

This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.

bioRxiv · Feb 7, 2022Immunology

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

T. L. Darling, B. Ying, B. Whitener, L. VanBlargan, T. L. Bricker, C.-Y. Liang, A. Joshi, G. Bamunuarachchi, K. Seehra, A. Schmitz, P. Halfmann, Y. Kawaoka, S. Elbashir, D. K. Edwards, L. Thackray, , A. Boon

This study evaluates the efficacy of mRNA-1273 and Ad26.COV2.S vaccines against the B.1.621 variant in mice and hamsters, showing protection against infection and pathology.

bioRxiv · Dec 29, 2021Microbiology

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

bioRxiv · Oct 23, 2021 · PreprintImmunology

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

B. Ying, B. Whitener, L. A. VanBlargan, A. O. Hassan, S. Shrihari, C.-Y. Liang, C. E. Karl, S. Mackin, R. E. Chen, N. M. Kafai, S. H. Wilks, D. J. Smith, J. M. Carreno, G. Singh, F. Krammer, , M. S. Diamond

This study evaluates the protective efficacy of mRNA vaccines against SARS-CoV-2 variants in mice, showing that low-dose vaccines lead to breakthrough infections with Delta variant.

bioRxiv · Aug 25, 2021Microbiology

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants

A. Choi, M. Koch, K. Wu, G. Dixon, J. Oestreicher, H. Legault, G. B. E. Stewart-Jones, T. Colpitts, R. Pajon, H. Bennett, A. Carfi, D. K. Edwards

This study evaluates the neutralizing activity of mRNA-1273 vaccine-induced sera against SARS-CoV-2 variants, finding reduced but still effective neutralization against several variants compared to the wild-type virus.

bioRxiv · Jun 28, 2021Microbiology

Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

K. S. Corbett, A. Werner, S. O'Connell, M. Gagne, L. Lai, J. Moliva, B. Flynn, A. Choi, M. Koch, K. E. Foulds, S. Andrew, D. Flebbe, E. Lamb, S. T. Nurmukhambetova, S. Provost, , M. Suthar

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

bioRxiv · May 21, 2021 · PreprintImmunology

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

K. Wu, A. Choi, M. Koch, S. Elbashir, L. Ma, D. Lee, A. Woods, C. Henry, C. Palandjian, A. Hill, H. Jani, J. Quinones, N. Nunna, S. O'Connell, A. B. McDermott, , D. K. Edwards

This study evaluates updated SARS-CoV-2 mRNA vaccines in mice, showing that mRNA-1273.351 boosts neutralization against B.1.351 and mRNA-1273.211 provides broad cross-variant protection.

bioRxiv · Apr 13, 2021Microbiology

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

K. Wu, A. P. Werner, J. I. Moliva, M. Koch, A. Choi, G. B. E. Stewart-Jones, H. Bennett, S. Boyoglu-Barnum, W. Shi, B. S. Graham, A. Carfi, K. S. Corbett, R. A. Seder, D. K. Edwards

This study evaluates the neutralizing antibody response of mRNA-1273 vaccine against SARS-CoV-2 variants B.1.1.7 and B.1.351 using pseudovirus neutralization assays.

bioRxiv · Jan 25, 2021 · PreprintImmunology